Additionally, a prior study has pointed out that BCL9 could enhance β-catenin-mediated transcriptional activity, and that BCL9 knockdown reduced tumor burden, metastasis, and angiogenesis via inhibition on the expression of c-Myc, cyclin D1, cluster of differentiation 44 (CD44), and vascular endothelial growth factor [18]. The gene discussed is BCL9; the disease is neoplasm.